Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

Main Article Content

Richard Warren
Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester

Howard Sofen
UCLA School of Medicine

Shinichi Imafuku
Fukuoka University Hospital

Jacek Szepietowski
Wroclaw Medical University

Andrew Blauvelt
Oregon Medical Research Center

Lynda Spelman
Veracity Clinical Research

Jessica Toms
Bristol Myers Squibb

Alex Buck
Bristol Myers Squibb and Cytel Inc

Subhashis Banerjee
Bristol Myers Squibb

Alan Menter
Baylor University Medical Center

Keywords

deucravacitinib, plaque psoriasis, POETYK

Abstract

N/A

References

1. SOTYKTU™ (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022.

2. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.

3. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

4. Armstrong AW, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02256-3. doi: 10.1016/j.jaad.2022.07.002. Online ahead of print.

5. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress, September 29–October 2, 2021. Late breaker.

6. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress, September 29–October 2, 2021.

7. Warren RB, et al. Presented at the EADV Spring Symposium; May 12–14, 2022.

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.48

Article Details

How to Cite
Warren, R., Sofen, H., Imafuku, S., Szepietowski, J., Blauvelt, A., Spelman, L., Toms, J., Buck, A., Banerjee, S., & Menter, A. (2022). Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. SKIN The Journal of Cutaneous Medicine, 6(6), s48. https://doi.org/10.25251/skin.6.supp.48
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Poster Presentations from FC22 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>